Peter Gierschik

Years Active: 2021-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Müller, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Acquired BTK mutations associated with resistance to non-covalent BTK inhibitors. Blood advances (2023)
Julia Zinngrebe, Barbara Moepps, Thomas Monecke, Peter Gierschik, Ferdinand Schlichtig, Thomas F E Barth, Gudrun Strauß, Elena Boldrin, Carsten Posovszky, Ansgar Schulz, Ortraud Beringer, Eva Rieser, Eva-Maria Jacobsen, Myriam Ricarda Lorenz, Klaus Schwarz, Ulrich Pannicke, Henning Walczak, Dierk Niessing, Catharina Schuetz, Pamela Fischer-Posovszky, Klaus-Michael Debatin
Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS. EMBO molecular medicine 14 (3) (2022)
Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A Fox, Klaus-Michael Debatin, Lueder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer
Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood (2021)

Peter Gierschik.css-eqlu8i{font-size:small;padding-left:4px;}